Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ABBV-181 in HIV-1 Infected Adults

NCT04223804 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04223804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04223804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ABBV-181 in HIV-1 Infected Adults
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
January 30, 2020
Completion date
February 27, 2023
Enrollment
41 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection, hiv-1, human immunodeficiency virus (hiv)